BioMarin Pharmaceutical Company Profile (NASDAQ:BMRN)

About BioMarin Pharmaceutical

BioMarin Pharmaceutical logoBioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company's product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Its products in clinical development include Kyndrisa, Pegvaliase, Reveglucosidase alfa, Vosoritide (formerly BMN 111), Cerliponase alfa, BMN 044, BMN 045, BMN 053 and BMN 270. Vimizim is an enzyme replacement therapy for the treatment of mucopolysaccharidosis type IV (MPS IV A). Naglazyme is a recombinant form of N-acetylgalactosamine 4-sulfatase (arylsulfatase B) indicated for patients with mucopolysaccharidosis VI (MPS VI). Kuvan is a synthetic oral form of 6R-BH4 indicated for patients with phenylketonuria (PKU).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: BMRN
  • CUSIP: 09061G10
Key Metrics:
  • Previous Close: $90.24
  • 50 Day Moving Average: $87.94
  • 200 Day Moving Average: $89.13
  • 52-Week Range: $72.96 - $102.49
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -80.89
  • P/E Growth: -0.96
  • Market Cap: $15.44B
  • Outstanding Shares: 171,987,000
  • Beta: 1.58
  • Net Margins: -46.22%
  • Return on Equity: -8.54%
  • Return on Assets: -5.51%
  • Debt-to-Equity Ratio: 0.25%
  • Current Ratio: 4.42%
  • Quick Ratio: 3.50%
Additional Links:
Companies Related to BioMarin Pharmaceutical:

Analyst Ratings

Consensus Ratings for BioMarin Pharmaceutical (NASDAQ:BMRN) (?)
Ratings Breakdown: 5 Hold Ratings, 14 Buy Ratings
Consensus Rating:Buy (Score: 2.74)
Consensus Price Target: $113.95 (26.90% upside)

Analysts' Ratings History for BioMarin Pharmaceutical (NASDAQ:BMRN)
DateFirmActionRatingPrice TargetDetails
2/10/2017GabelliReiterated RatingBuyView Rating Details
2/8/2017WedbushReiterated RatingNeutral$102.00View Rating Details
2/7/2017Morgan StanleyInitiated CoverageOverweight$110.00View Rating Details
1/23/2017Credit Suisse GroupInitiated CoverageOutperform -> Outperform$111.00 -> $107.00View Rating Details
1/9/2017Robert W. BairdSet Price TargetBuy$115.00View Rating Details
12/9/2016Cowen and CompanySet Price TargetBuy$150.00View Rating Details
11/29/2016Barclays PLCDowngradeOverweight -> Equal Weight$125.00 -> $105.00View Rating Details
11/7/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$105.00 -> $84.00View Rating Details
11/3/2016Deutsche Bank AGInitiated CoverageBuy$106.00View Rating Details
10/31/2016J P Morgan Chase & CoReiterated RatingBuy$127.00View Rating Details
10/30/2016RBC Capital MarketsSet Price TargetBuy$125.00View Rating Details
10/13/2016Leerink SwannReiterated RatingOutperform$127.00View Rating Details
10/7/2016Goldman Sachs Group, Inc. (The)UpgradeNeutralView Rating Details
8/17/2016Jefferies Group LLCReiterated RatingBuyView Rating Details
8/5/2016Stifel NicolausBoost Price TargetBuy$107.00 -> $113.00View Rating Details
7/28/2016William BlairSet Price TargetBuy$116.00View Rating Details
6/20/2016Oppenheimer Holdings, Inc.Reiterated RatingMarket Perform$99.00View Rating Details
5/31/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details
4/7/2016BMO Capital MarketsInitiated CoverageOutperform$99.00View Rating Details
1/15/2016Bank of America CorpReiterated RatingBuy$165.00 -> $135.00View Rating Details
10/13/2015Raymond James Financial, Inc.Reiterated RatingOutperform$157.00View Rating Details
8/4/2015NomuraReiterated RatingBuy$163.00 -> $173.00View Rating Details
8/4/2015SunTrust Banks, Inc.Reiterated RatingBuyView Rating Details
6/18/2015Canaccord GenuityBoost Price TargetBuy$115.00 -> $150.00View Rating Details
2/26/2015Brean CapitalReiterated RatingHoldView Rating Details
2/26/2015Citigroup Inc.Reiterated RatingBuy$94.00 -> $133.00View Rating Details
(Data available from 2/23/2015 forward)


Earnings History for BioMarin Pharmaceutical (NASDAQ:BMRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017Q416($0.38)$296.54 millionN/AView Earnings Details
10/27/2016Q316($0.39)($0.26)$289.70 million$279.90 millionViewListenView Earnings Details
8/4/2016Q216($0.52)($2.61)$278.75 million$300.10 millionViewN/AView Earnings Details
4/28/2016Q116($0.85)($0.53)$240.21 million$236.70 millionViewListenView Earnings Details
2/25/2016Q415$0.67$0.39$224.14 million$227.90 millionViewListenView Earnings Details
10/29/2015Q315($0.65)($0.60)$216.32 million$208.90 millionViewListenView Earnings Details
8/3/2015Q215($0.53)($0.51)$218.16 million$250.50 millionViewN/AView Earnings Details
4/30/2015Q1($0.53)($0.43)$201.30 millionViewN/AView Earnings Details
2/25/2015Q414($0.59)($0.47)$189.01 million$230.90 millionViewN/AView Earnings Details
10/23/2014Q314($0.22)($0.16)$206.00 million$176.80 millionViewListenView Earnings Details
7/30/2014Q214($0.41)($0.23)$159.70 million$191.70 millionViewN/AView Earnings Details
5/1/2014($0.44)($0.01)$145.16 million$151.60 millionViewN/AView Earnings Details
2/26/2014Q413($0.35)($0.11)$146.07 million$146.90 millionViewN/AView Earnings Details
10/24/2013Q313($0.30)($0.38)$140.00 million$136.90 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.29)($0.16)$134.33 million$136.80 millionViewN/AView Earnings Details
4/25/2013Q1 2013($0.30)($0.31)$131.35 million$127.90 millionViewN/AView Earnings Details
2/21/2013Q4 2012($0.22)($0.43)$129.70 million$130.96 millionViewN/AView Earnings Details
10/25/2012($0.20)($0.04)ViewN/AView Earnings Details
8/1/2012($0.19)($0.27)ViewN/AView Earnings Details
4/26/2012($0.15)($0.21)ViewN/AView Earnings Details
2/16/2012($0.10)($0.23)ViewN/AView Earnings Details
10/27/2011($0.10)($0.16)ViewN/AView Earnings Details
7/28/2011($0.09)($0.05)ViewN/AView Earnings Details
4/28/2011($0.10)$0.14ViewN/AView Earnings Details
2/17/2011($0.02)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)
Current Year EPS Consensus Estimate: $-3.73 EPS
Next Year EPS Consensus Estimate: $-1.11 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20166($2.51)($0.40)($0.94)
Q2 20166($4.02)($0.27)($2.11)
Q3 20166($0.63)($0.24)($0.41)
Q4 20165($0.67)($0.26)($0.50)
Q1 20171($0.44)($0.44)($0.44)
Q2 20172($0.35)($0.25)($0.30)
Q3 20171($0.31)($0.31)($0.31)
Q4 20172($0.25)($0.25)($0.25)
(Data provided by Zacks Investment Research)


Dividend History for BioMarin Pharmaceutical (NASDAQ:BMRN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for BioMarin Pharmaceutical (NASDAQ:BMRN)
Insider Ownership Percentage: 2.50%
Institutional Ownership Percentage: 97.78%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/26/2017Jean Jacques BienaimeCEOSell10,000$84.22$842,200.00View SEC Filing  
1/11/2017Jean Jacques BienaimeCEOSell8,000$90.58$724,640.00View SEC Filing  
1/9/2017Daniel K SpiegelmanCFOSell5,000$90.00$450,000.00View SEC Filing  
1/9/2017Jean Jacques BienaimeCEOSell8,000$88.49$707,920.00View SEC Filing  
12/30/2016Jean Jacques BienaimeCEOSell8,000$83.60$668,800.00View SEC Filing  
11/22/2016Jean Jacques BienaimeCEOSell69,743$85.69$5,976,277.67View SEC Filing  
11/21/2016Jean Jacques BienaimeCEOSell69,744$87.56$6,106,784.64View SEC Filing  
11/8/2016Jean Jacques BienaimeCEOSell140,000$82.67$11,573,800.00View SEC Filing  
11/7/2016Jean Jacques BienaimeCEOSell70,000$82.52$5,776,400.00View SEC Filing  
10/28/2016Jean Jacques BienaimeCEOSell120,000$81.30$9,756,000.00View SEC Filing  
10/17/2016Jean Jacques BienaimeCEOSell41,666$84.39$3,516,193.74View SEC Filing  
10/14/2016Jean Jacques BienaimeCEOSell64,125$86.96$5,576,310.00View SEC Filing  
9/29/2016Jean Jacques BienaimeCEOSell53,125$93.65$4,975,156.25View SEC Filing  
9/27/2016Jeffrey Robert AjerEVPSell18,467$95.61$1,765,629.87View SEC Filing  
9/16/2016Jean Jacques BienaimeCEOSell137,368$95.34$13,096,665.12View SEC Filing  
8/26/2016Henry J FuchsEVPSell15,000$95.06$1,425,900.00View SEC Filing  
8/16/2016Jean Jacques BienaimeCEOSell41,666$91.49$3,812,022.34View SEC Filing  
8/1/2016Brian MuellerVPSell287$100.00$28,700.00View SEC Filing  
8/1/2016Daniel K SpiegelmanCFOSell4,000$99.33$397,320.00View SEC Filing  
8/1/2016George Eric DavisEVPSell2,167$100.00$216,700.00View SEC Filing  
7/27/2016V Bryan LawlisDirectorSell1,100$95.39$104,929.00View SEC Filing  
7/22/2016V Bryan LawlisDirectorSell6,400$95.01$608,064.00View SEC Filing  
7/18/2016Jean Jacques BienaimeCEOSell41,666$92.72$3,863,271.52View SEC Filing  
7/7/2016George Eric DavisEVPSell2,167$90.00$195,030.00View SEC Filing  
6/20/2016V Bryan LawlisDirectorSell550$82.77$45,523.50View SEC Filing  
6/16/2016Jean Jacques BienaimeCEOSell41,666$80.55$3,356,196.30View SEC Filing  
6/6/2016Daniel K SpiegelmanCFOSell1,649$89.14$146,991.86View SEC Filing  
5/31/2016Daniel K SpiegelmanCFOSell20,841$89.88$1,873,189.08View SEC Filing  
5/26/2016Henry J FuchsEVPSell15,000$87.81$1,317,150.00View SEC Filing  
5/23/2016Daniel K SpiegelmanCFOSell3,769$87.07$328,166.83View SEC Filing  
5/18/2016Robert BaffiEVPSell5,000$87.05$435,250.00View SEC Filing  
5/10/2016George Eric DavisEVPSell14,658$85.11$1,247,542.38View SEC Filing  
5/5/2016Jean Jacques BienaimeCEOSell50,000$80.15$4,007,500.00View SEC Filing  
5/3/2016Jeffrey Robert AjerEVPSell415$86.03$35,702.45View SEC Filing  
5/2/2016Jean Jacques BienaimeCEOSell36,500$85.01$3,102,865.00View SEC Filing  
3/14/2016George Eric DavisEVPSell1,996$86.21$172,075.16View SEC Filing  
3/4/2016Jeffrey Robert AjerSVPSell1,255$88.42$110,967.10View SEC Filing  
3/2/2016Daniel K SpiegelmanCFOSell4,623$86.12$398,132.76View SEC Filing  
3/1/2016Jean Jacques BienaimeCEOSell10,000$84.28$842,800.00View SEC Filing  
2/22/2016Michael G GreyDirectorSell7,500$80.00$600,000.00View SEC Filing  
12/16/2015George Eric DavisSVPSell1,362$100.00$136,200.00View SEC Filing  
11/30/2015Jean Jacques BienaimeCEOSell1,000$94.74$94,740.00View SEC Filing  
11/16/2015Daniel K. SpiegelmanCFOSell20,000$104.30$2,086,000.00View SEC Filing  
11/16/2015V Bryan LawlisDirectorSell8,550$106.90$913,995.00View SEC Filing  
10/15/2015Jean Jacques BienaimeCEOSell1,000$108.24$108,240.00View SEC Filing  
9/14/2015Jean Jacques BienaimeCEOSell1,000$131.43$131,430.00View SEC Filing  
7/20/2015Jeffrey Robert AjerSVPSell3,000$150.00$450,000.00View SEC Filing  
7/7/2015Jean Jacques BienaimeCEOSell1,500$139.07$208,605.00View SEC Filing  
6/5/2015Daniel K SpiegelmanCFOSell1,649$122.30$201,672.70View SEC Filing  
6/5/2015Henry J FuchsEVPSell1,864$122.32$228,004.48View SEC Filing  
6/4/2015Jeffrey Robert AjerSVPSell1,362$122.35$166,640.70View SEC Filing  
6/1/2015Daniel K SpiegelmanCFOSell5,523$124.73$688,883.79View SEC Filing  
6/1/2015Jeffrey Robert AjerSVPSell377$123.76$46,657.52View SEC Filing  
5/29/2015Daniel K SpiegelmanCFOSell1,578$126.15$199,064.70View SEC Filing  
5/26/2015Jeffrey Robert AjerSVPSell1,625$126.55$205,643.75View SEC Filing  
5/18/2015Daniel K SpiegelmanCFOSell2,059$124.77$256,901.43View SEC Filing  
5/18/2015George Eric DavisSVPSell2,558$125.26$320,415.08View SEC Filing  
5/18/2015Henry J FuchsEVPSell1,864$124.78$232,589.92View SEC Filing  
5/13/2015Henry J FuchsEVPSell1,434$121.37$174,044.58View SEC Filing  
5/11/2015Henry J FuchsEVPSell2,869$121.64$348,985.16View SEC Filing  
3/17/2015Jean Jacques BienaimeCEOSell2,000$124.17$248,340.00View SEC Filing  
3/16/2015Henry J FuchsEVPSell41,315$123.57$5,105,294.55View SEC Filing  
3/16/2015Jean Jacques BienaimeCEOSell1,000$123.48$123,480.00View SEC Filing  
3/10/2015Jean Jacques BienaimeCEOSell21,021$112.39$2,362,550.19View SEC Filing  
3/9/2015Jean Jacques BienaimeCEOSell19,000$112.13$2,130,470.00View SEC Filing  
3/5/2015Jean Jacques BienaimeCEOSell10,000$113.70$1,137,000.00View SEC Filing  
3/5/2015Robert BaffiEVPSell14,051$116.37$1,635,114.87View SEC Filing  
3/4/2015Jean Jacques BienaimeCEOSell13,916$107.92$1,501,814.72View SEC Filing  
3/3/2015Jean Jacques BienaimeCEOSell5,000$107.42$537,100.00View SEC Filing  
3/2/2015Daniel K SpiegelmanCFOSell15,500$107.00$1,658,500.00View SEC Filing  
3/2/2015George Eric DavisSVPSell23,000$108.31$2,491,130.00View SEC Filing  
3/2/2015Jean Jacques BienaimeCEOSell5,000$108.44$542,200.00View SEC Filing  
1/9/2015Jean Jacques BienaimeCEOSell2,000$94.14$188,280.00View SEC Filing  
12/24/2014Jean Jacques BienaimeCEOSell5,000$88.73$443,650.00View SEC Filing  
12/10/2014Jean Jacques BienaimeCEOSell2,000$95.00$190,000.00View SEC Filing  
12/4/2014Alan LewisDirectorSell7,500$89.90$674,250.00View SEC Filing  
12/2/2014Brian MuellerVPSell11,950$90.91$1,086,374.50View SEC Filing  
11/25/2014George Eric DavisSVPSell20,000$89.75$1,795,000.00View SEC Filing  
11/25/2014Jean Jacques BienaimeCEOSell2,000$90.00$180,000.00View SEC Filing  
11/12/2014Jean Jacques BienaimeCEOSell1,000$81.51$81,510.00View SEC Filing  
11/10/2014Henry J FuchsEVPSell20,000$86.55$1,731,000.00View SEC Filing  
11/10/2014Jean Jacques BienaimeCEOSell4,000$87.00$348,000.00View SEC Filing  
11/3/2014Jean Jacques BienaimeCEOSell3,000$85.33$255,990.00View SEC Filing  
11/3/2014Jeffrey Robert AjerSVPSell47$83.54$3,926.38View SEC Filing  
10/30/2014Robert BaffiEVPSell75,425$81.34$6,135,069.50View SEC Filing  
10/24/2014Jean Jacques BienaimeCEOSell2,000$80.00$160,000.00View SEC Filing  
9/19/2014George Eric DavisSVPSell17,536$69.75$1,223,136.00View SEC Filing  
9/2/2014Daniel K SpiegelmanCFOSell16,000$69.83$1,117,280.00View SEC Filing  
8/20/2014Jean Jacques BienaimeCEOSell5,000$70.00$350,000.00View SEC Filing  
8/5/2014Henry J FuchsEVPSell10,000$65.00$650,000.00View SEC Filing  
8/1/2014Daniel K SpiegelmanCFOSell2,229$61.76$137,663.04View SEC Filing  
7/2/2014Daniel K SpiegelmanCFOSell2,229$64.00$142,656.00View SEC Filing  
6/4/2014Jean Jacques BienaimeCEOSell2,000$61.20$122,400.00View SEC Filing  
5/22/2014Jean Jacques BienaimeCEOSell1,000$56.88$56,880.00View SEC Filing  
5/21/2014Jean Jacques BienaimeCEOSell1,545$56.19$86,813.55View SEC Filing  
5/16/2014Henry FuchsEVPSell1,864$56.86$105,987.04View SEC Filing  
5/16/2014Jeffrey Robert AjerSVPSell1,004$56.91$57,137.64View SEC Filing  
5/16/2014V Bryan LawlisDirectorSell1,700$56.87$96,679.00View SEC Filing  
5/13/2014Henry FuchsEVPSell1,434$58.23$83,501.82View SEC Filing  
5/9/2014Henry FuchsEVPSell3,479$57.91$201,468.89View SEC Filing  
2/3/2014Henry FuchsEVPSell10,000$67.70$677,000.00View SEC Filing  
12/24/2013Jean Jacques BienaimeCEOSell10,000$68.71$687,100.00View SEC Filing  
12/5/2013Jean Jacques BienaimeCEOSell5,000$69.70$348,500.00View SEC Filing  
10/16/2013Jean Jacques BienaimeCEOSell2,000$67.73$135,460.00View SEC Filing  
10/10/2013Jean Jacques BienaimeCEOSell3,000$66.76$200,280.00View SEC Filing  
9/19/2013Henry FuchsEVPSell10,000$80.19$801,900.00View SEC Filing  
9/16/2013Jean Jacques BienaimeCEOSell2,000$73.08$146,160.00View SEC Filing  
9/9/2013Robert BaffiEVPSell20,000$73.00$1,460,000.00View SEC Filing  
9/5/2013Henry J FuchsEVPSell10,000$70.00$700,000.00View SEC Filing  
9/4/2013Daniel K SpiegelmanCFOSell9,000$69.00$621,000.00View SEC Filing  
8/15/2013Jean Jacques BienaimeCEOSell1,000$64.36$64,360.00View SEC Filing  
7/1/2013Daniel K SpiegelmanCFOSell4,066$59.78$243,065.48View SEC Filing  
7/1/2013Henry J FuchsEVPSell10,000$60.00$600,000.00View SEC Filing  
6/3/2013Henry J FuchsEVPSell1,098$58.32$64,035.36View SEC Filing  
5/23/2013Henry J FuchsEVPSell20,609$66.29$1,366,170.61View SEC Filing  
5/22/2013Mark WoodVPSell3,103$67.12$208,273.36View SEC Filing  
5/21/2013Jean Jacques BienaimeCEOSell2,000$64.14$128,280.00View SEC Filing  
5/16/2013Jean Jacques BienaimeCEOSell12,000$67.90$814,800.00View SEC Filing  
5/14/2013Brian MuellerVPSell4,947$70.35$348,021.45View SEC Filing  
5/14/2013George Eric DavisSVPSell20,000$70.34$1,406,800.00View SEC Filing  
5/14/2013Jean Jacques BienaimeCEOSell15,000$70.17$1,052,550.00View SEC Filing  
5/13/2013Jean Jacques BienaimeCEOSell15,800$68.77$1,086,566.00View SEC Filing  
5/13/2013Jeffrey Robert AjerSVPSell1,248$69.26$86,436.48View SEC Filing  
5/8/2013Jean Jacques BienaimeCEOSell4,000$65.87$263,480.00View SEC Filing  
5/2/2013Jean Jacques BienaimeCEOSell3,000$64.99$194,970.00View SEC Filing  
4/10/2013Robert BaffiEVPSell20,000$64.00$1,280,000.00View SEC Filing  
3/22/2013Mark WoodVPSell3,103$60.21$186,831.63View SEC Filing  
3/4/2013George Eric DavisSVPSell4,000$60.18$240,720.00View SEC Filing  
2/22/2013Mark WoodVPSell3,103$55.22$171,347.66View SEC Filing  
2/4/2013Jean Jacques BienaimeCEOSell2,000$55.77$111,540.00View SEC Filing  
12/27/2012Jean Jacques BienaimeCEOSell17,000$48.37$822,290.00View SEC Filing  
11/12/2012George Eric DavisSVPSell99,075$48.45$4,800,183.75View SEC Filing  
9/4/2012Henry J FuchsEVPSell5,000$37.76$188,800.00View SEC Filing  
8/22/2012Mark WoodVPSell2,665$37.93$101,083.45View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for BioMarin Pharmaceutical (NASDAQ:BMRN)
DateHeadline logo3 Biotech Stocks You May Be Overlooking (NASDAQ:BMRN) - February 22 at 3:57 PM
News IconWhy Investors remained confident on BioMarin Pharmaceutical Inc. (BMRN), McCormick & Company, Incorporated ... - StockNewsJournal (NASDAQ:BMRN) - February 21 at 3:20 PM logoJANA Partners Made Massive New Pharma Investments in Q4 (NASDAQ:BMRN) - February 21 at 3:20 PM
News IconWhy Analysts put forward these two stocks: BioMarin Pharmaceutical Inc. (BMRN), McCormick & Company ... - The USA Commerce (NASDAQ:BMRN) - February 21 at 11:46 AM
News IconStock Price of BioMarin Pharmaceutical Inc. (BMRN) Decreases -0.29% - Highland Mirror (NASDAQ:BMRN) - February 21 at 11:46 AM logoBlog Coverage Celgene's Multiple Sclerosis Drug Reported Positive Phase-III Results (NASDAQ:BMRN) - February 21 at 11:46 AM logoBetter Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - February 20 at 10:13 AM logoBioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again? (NASDAQ:BMRN) - February 17 at 6:11 PM logoBioMarin Pharmaceutical : Announces 11 Presentations at 13th Annual WORLDSymposium(TM) 2017 (NASDAQ:BMRN) - February 16 at 4:03 PM logoBiomarin Pharma To Participate In Leerink Partners Global Conference At 1:00 PM (NASDAQ:BMRN) - February 16 at 4:03 PM
News IconAre Analysts Optimistic About Where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is Heading? - Winfield Review (NASDAQ:BMRN) - February 16 at 7:56 AM
News IconTrading Spotlight on Shares of BioMarin Pharmaceutical Inc. (BMRN) - Midway Monitor (NASDAQ:BMRN) - February 16 at 7:56 AM logoBioMarin Announces 11 Presentations at 13th Annual WORLDSymposium™ 2017 (NASDAQ:BMRN) - February 16 at 7:56 AM logoBioMarin Pharmaceutical Inc. - Strategy, SWOT and Corporate Finance Report - New Study Released (NASDAQ:BMRN) - February 14 at 4:33 PM logoAnalyst Activity – Gabelli Reiterates Buy on BioMarin Pharmaceutical (NASDAQ:BMRN) (NASDAQ:BMRN) - February 12 at 3:57 PM
News IconBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Price Target At $114 - Transcript Daily (NASDAQ:BMRN) - February 10 at 3:28 PM
News IconIs It Time to go for BioMarin Pharmaceutical Inc. (BMRN), Dr Pepper ... - StockNewsJournal (NASDAQ:BMRN) - February 10 at 3:28 PM
News IconInvestor Center: Tracking the Numbers for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - The Standard (NASDAQ:BMRN) - February 9 at 2:14 AM logoBioMarin to Attend Three Investor Conferences in 1Q17 (NASDAQ:BMRN) - February 8 at 4:11 PM
News IconMonitoring the Levels for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Providence Standard (NASDAQ:BMRN) - February 8 at 3:00 AM logoMorgan Stanley Starts BioMarin Pharmaceutical Inc. (BMRN) at ... - (NASDAQ:BMRN) - February 8 at 3:00 AM logoBioMarin to Host Fourth Quarter and Full Year 2016 Financial Results Conference Call and Webcast on Thursday, … (NASDAQ:BMRN) - February 7 at 4:57 PM logoAnalyst Activity – Morgan Stanley Initiates Coverage On BioMarin Pharmaceutical (NASDAQ:BMRN) With a Overweight (NASDAQ:BMRN) - February 7 at 4:57 PM
News IconBioMarin Pharmaceutical (BMRN) is Initiated by Morgan Stanley to "Overweight" (NASDAQ:BMRN) - February 7 at 4:57 PM logoCoverage initiated on BioMarin Pharm by Morgan Stanley (NASDAQ:BMRN) - February 7 at 4:57 PM logoBioMarin to Host Fourth Quarter and Full Year 2016 Financial Results Conference Call and Webcast on Thursday, February 23 at 4:30pm ET (NASDAQ:BMRN) - February 7 at 4:57 PM logoBioMarin sues to stop generic version of its $90Ka-year drug - San Francisco Business Times (NASDAQ:BMRN) - February 6 at 8:59 PM logoBioMarin sues to stop generic version of its $90K-a-year drug (NASDAQ:BMRN) - February 6 at 8:59 PM
News IconConsensus Price Of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Set At $114.235 - Transcript Daily (NASDAQ:BMRN) - February 5 at 8:59 PM
News IconIs BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Preparing For A Breakout Trade? - Post Analyst (NASDAQ:BMRN) - February 3 at 4:07 PM logoBRIEF-Jennison Associates Llc reports 5.4 pct passive stake in Biomarin Pharmaceutical (NASDAQ:BMRN) - February 2 at 9:10 PM logoBioMarin Pharma (BMRN) Reports PRIME Regulatory Support for BMN 270 Gene Therapy in Hemophilia A (NASDAQ:BMRN) - February 2 at 4:07 PM logoBioMarin Receives Access to Priority Medicines (PRIME) Regulatory Support from EMA for BMN 270 Gene Therapy in Hemophilia A (NASDAQ:BMRN) - February 2 at 4:07 PM logo4:16 pm BioMarin Pharm announces that the European Medicines Agency has granted access to its Priority Medicines regulatory initiative for the company's investigational gene therapy treatment for severe hemophilia A, BMN 270 (NASDAQ:BMRN) - February 2 at 4:07 PM logoBioMarin's Hemophilia Candidate Included in PRIME Initiative (NASDAQ:BMRN) - February 2 at 4:07 PM logoBioMarin Pharma (BMRN) Reports PRIME Regulatory Support for BMN 270 Gene Therapy in Hemophilia A - (NASDAQ:BMRN) - February 1 at 9:13 PM logoBioMarin Pharmaceutical (BMRN) Shares Cross Above 200 DMA (NASDAQ:BMRN) - February 1 at 4:11 PM
News IconTop Gainers of the Day: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) from Biotechnology (NASDAQ:BMRN) - January 31 at 4:16 PM logo4 Top Biotech Stocks With Big Upcoming Catalysts (NASDAQ:BMRN) - January 31 at 4:16 PM
News IconSell-side Taking Aim at Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Aiken Advocate (NASDAQ:BMRN) - January 30 at 3:51 PM logoBioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : January 30, 2017 (NASDAQ:BMRN) - January 30 at 3:51 PM
News IconChief Executive Officer of BioMarin Pharmaceutical Inc (NASDAQ:BMRN), Bienaime Jean Jacques, sells 5,000 shares worth $422,200 (NASDAQ:BMRN) - January 28 at 3:56 PM
News IconIs BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a large market cap stock a smart buy? (NASDAQ:BMRN) - January 28 at 3:56 PM
News IconBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock ABR At 1.47 - Stock Observer (NASDAQ:BMRN) - January 27 at 4:32 PM logoTraders Watch list: Charter Communications, Inc. (CHTR), BioMarin Pharmaceutical Inc. (BMRN), SBA ... - iStreetWire (NASDAQ:BMRN) - January 26 at 4:39 PM logoIs BioMarin (BMRN) Well Poised for Growth in 2017? (NASDAQ:BMRN) - January 26 at 4:39 PM
News IconTechnical Trading Review on Shares of BioMarin Pharmaceutical Inc. (BMRN) - Market Point (NASDAQ:BMRN) - January 26 at 2:53 AM
News IconBiomarin Pharmaceutical INC (BMRN) Market Value Rose While Longwood Capital Partners LLC Has Lowered Its Holding by $3.13 Million (NASDAQ:BMRN) - January 24 at 4:30 PM
News IconAnalysts Take: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Projected Earnings & Price Targets - Aiken Advocate (NASDAQ:BMRN) - January 23 at 3:39 PM logoWhy Credit Suisse Sees 25% Upside at BioMarin - 24/7 Wall St. (NASDAQ:BMRN) - January 23 at 3:39 PM


What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

Where is BioMarin Pharmaceutical's stock going? Where will BioMarin Pharmaceutical's stock price be in 2017?

19 brokerages have issued 12 month price targets for BioMarin Pharmaceutical's shares. Their forecasts range from $84.00 to $150.00. On average, they anticipate BioMarin Pharmaceutical's share price to reach $113.95 in the next twelve months.

When will BioMarin Pharmaceutical announce their earnings?

BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

What are analysts saying about BioMarin Pharmaceutical stock?

Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:

  • According to Zacks Investment Research, "BioMarin should continue to see growth in both its orphan disease drugs – Vimizim and Kuvan – in 2017. Robust patient growth and penetration should propel the drugs’ sales. The company’s progress with its pipeline has been impressive. Moreover, loss estimates have narrowed lately ahead of the company's Q4 results. Its stock has outperformed the Zacks classified Medical-Biomedical and Genetics industry in the past one year. However, BioMarin has suffered quite a few regulatory setbacks related to its pipeline candidates, Brineura and Kyndrisa. Delayed approvals or development setbacks could have a negative impact on the stock. Also, the company’s top line is under pressure due to political and macroeconomic instability in Brazil and the Middle East. Meanwhile, BioMarin is facing generic threat for key drug Kuvan. The earlier-than-expected entry of generics would be a huge blow for the company." (2/1/2017)

  • Cowen and Company analysts commented, "We believe 2H16 conservatism leaves shares poised to move higher.   We look favorably on TMO’s Q2 result and updated 2016 outlook, which includes a faster rate of organic revenue growth (+~4.5% vs. prior ~+4%) and operating margin expansion at the high end of previous guidance (+60-70 bps y/y vs. prior +50-70 bps). We continue to believe that TMO’s diversification and broad-based growth will insulate the co.’s performance, and like mgmt’s conservative strategy of leaving a recovery in industrials (~10% of sales/~50% of industrial/ applied sales) and stability in foreign exchange rates as upside.   China and the Pharma/Biotech end-market continue to lead growth, rising mid-teens on a mid-teens comp and high-single digits on a mid-teens comp, respectively. In China, softness in pure industrial has been more than offset by strength in applied (with an emphasis on environmental protection and food safety), healthcare, and life sciences (the convergence of tools, diagnostics, and precision medicine). While bioproduction was cited as the strongest of TMO’s Pharma/Biotech businesses in the quarter, growth in this end market remains solid across customer type, geography, and utility (e.g. production vs. research and discovery)." (7/28/2016)

Who owns BioMarin Pharmaceutical stock?

BioMarin Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional investors include Sands Capital Management LLC (5.45%), State Street Corp (2.18%), Temasek Holdings Private Ltd (2.02%), Palo Alto Investors LLC (1.14%), Viking Global Investors LP (0.81%) and William Blair Investment Management LLC (0.64%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Robert Baffi and V Bryan Lawlis.

Who sold BioMarin Pharmaceutical stock? Who is selling BioMarin Pharmaceutical stock?

BioMarin Pharmaceutical's stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Fred Alger Management Inc., William Blair Investment Management LLC, TCW Group Inc., FIL Ltd, Ithaka Group LLC, GLG LLC and GSA Capital Partners LLP. Company insiders that have sold BioMarin Pharmaceutical stock in the last year include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Robert Baffi and V Bryan Lawlis.

Who bought BioMarin Pharmaceutical stock? Who is buying BioMarin Pharmaceutical stock?

BioMarin Pharmaceutical's stock was bought by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Marshall Wace LLP, AMF Pensionsforsakring AB, Asset Management One Co. Ltd., Palo Alto Investors LLC, State Street Corp, Frontier Capital Management Co. LLC and Alyeska Investment Group L.P..

How do I buy BioMarin Pharmaceutical stock?

Shares of BioMarin Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of BioMarin Pharmaceutical stock cost?

One share of BioMarin Pharmaceutical stock can currently be purchased for approximately $89.79.

BioMarin Pharmaceutical (NASDAQ:BMRN) Chart for Thursday, February, 23, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Earnings History Chart

Earnings by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Dividend History Chart

Dividend Payments by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Last Updated on 2/23/2017 by Staff